Epkinly (epcoritamab)

2026-05-21 — Genmab A/S (Nasdaq: GMAB) announced it will present/publish 23 abstracts across the 2026 ASCO Annual Meeting (Chicago; May 29–June 2) and the EHA 2026 Congress (Stockholm; June 11–14). Twenty abstracts involve epcoritamab, a subcutaneous CD3xCD20 bispecific T‑cell engager; four are oral presentations. Highlights include full Phase 3 EPCORE DLBCL‑1 results comparing epcoritamab monotherapy vs investigator’s choice chemo in relapsed/refractory large B‑cell lymphoma, and additional Phase 3 EPCORE FL‑1 data evaluating epcoritamab + rituximab/lenalidomide (R²) vs R² in relapsed/refractory follicular lymphoma. Genmab also listed three abstracts on late‑stage investigational medicines rinatabart sesutecan (Rina‑S; FRα‑targeted ADC; Phase 3 RAINFOL‑03/‑04 in endometrial/ovarian cancer) and petosemtamab (EGFR/LGR5 bispecific; Phase 2 with pembrolizumab in first‑line PD‑L1–high metastatic NSCLC). The release underscores breadth of clinical development and upcoming catalysts for hematologic and solid-tumor programs; investigational uses are not established.